Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial

Author:

Groop Per-Henrik123,Cooper Mark E.3,Perkovic Vlado4,Hocher Berthold567,Kanasaki Keizo89,Haneda Masakazu10,Schernthaner Guntram11,Sharma Kumar12,Stanton Robert C.13,Toto Robert14,Cescutti Jessica15,Gordat Maud15,Meinicke Thomas16,Koitka-Weber Audrey16,Thiemann Sandra17,von Eynatten Maximilian17

Affiliation:

1. Folkhälsan Institute of Genetics; Folkhälsan Research Center, Biomedicum Helsinki; Helsinki Finland

2. Abdominal Center Nephrology; University of Helsinki and Helsinki University Hospital; Helsinki Finland

3. Baker IDI Heart and Diabetes Institute; Melbourne Australia

4. The George Institute for Global Health, Faculty of Medicine; University of Sydney; Sydney Australia

5. Institute of Nutritional Science; University of Potsdam; Potsdam Germany

6. Department of Histology and Embryology; Medical College, Jinan University; Guangzhou China

7. IFLb, Institut für Laboratoriumsmedizin Berlin GmbH; Berlin Germany

8. Department of Diabetology and Endocrinology; Kanazawa Medical University; Kanazawa Japan

9. Division of Anticipatory Molecular Food Science and Technology; Medical Research Institute, Kanazawa Medical University; Kanazawa Japan

10. Division of Metabolism and Biosystemic Science, Department of Medicine; Asahikawa Medical University; Asahikawa Japan

11. Department of Internal Medicine; Rudolfstiftung Hospital; Vienna Austria

12. Department of Medicine, Center for Renal Translational Medicine; University of California; San Diego California

13. Joslin Diabetes Center; Harvard Medical School; Boston Massachusetts

14. Department of Internal Medicine; University of Texas Southwestern Medical Center; Dallas Texas

15. Boehringer Ingelheim France S.A.S; Reims France

16. Boehringer Ingelheim Pharma GmbH & Co. KG; Biberach Germany

17. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

Funder

Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3